MDCC Molecular Devices (MM)

SUNNYVALE, Calif., July 20 /PRNewswire-FirstCall/ -- Molecular Devices Corporation (NASDAQ:MDCC) today announced record revenues and earnings for the quarter ended June 30, 2006. Revenues for the quarter were a record $47.4 million, or an increase of 6% compared to the same period last year. On a GAAP basis, operating income was $2.0 million in the second quarter of 2006. GAAP operating income for the second quarter included a $4.3 million non-cash charge associated with the write-off of acquired in-process research and development related to the acquisition of the Arcturus Laser Capture Microdissection business and non-cash stock compensation expense of $1.3 million associated with the Company's adoption of Statement of Financial Accounting Standards No. 123R. On a non-GAAP basis, excluding the effects of the write-off of acquired in-process research and development and the non-cash stock compensation expense, operating income for the second quarter of 2006 was $7.6 million, or an increase of 26% compared to the same period last year. On a GAAP basis, fully diluted losses per share for the second quarter of 2006 were $0.03. On a non-GAAP basis, excluding the write-off of acquired in-process research and development and the non-cash stock compensation expense, fully diluted earnings per share increased 33% to $0.28 in the second quarter of 2006 from $0.21 in the same period last year. A table reconciling operating income and fully diluted earnings per share on a GAAP and non-GAAP basis is provided immediately following the Condensed Consolidated Balance Sheets. "We saw solid growth in our SpectraMax(R) and Meta life sciences imaging product lines during the quarter," stated Joseph D. Keegan, Ph.D., Molecular Devices' President and Chief Executive Officer. "Unfortunately, this growth was offset by declines in our Drug Discovery Imaging and Genomics product lines. Results from our recently acquired Laser Capture Microdissection business met our expectations during the quarter. We continue to believe that our worldwide life sciences market remains stable, but we have become more cautious on the outlook for drug discovery as a result of the weakness in imaging." The Company established guidance for the third quarter of 2006 and updated guidance for the full year 2006. For the third quarter of 2006, the Company anticipates revenues of $48 to $52 million, GAAP fully diluted earnings per share of $0.22 to $0.26 and non-GAAP fully diluted earnings per share of $0.27 to $0.31 excluding $0.05 of non-cash stock compensation expense. For the full year 2006, the Company anticipates revenues of $190 to $198 million, GAAP fully diluted earnings per share of $0.71 to $0.79 and non-GAAP fully diluted earnings per share of $1.10 to $1.18 excluding $0.20 per share of non-cash stock compensation expense, $0.06 per share gain on the sale of an equity investment and $0.25 per share write-off of acquired in-process research and development. Conference Call Information A conference call to discuss our second quarter results, 2006 guidance and other matters related to our business is scheduled for Thursday, July 20, 2006 at 1:30 p.m. Pacific (4:30 p.m. Eastern). Interested parties can participate in the call by dialing 800-257-3401 (domestic) or 303-205-0033 (international). Replay dial-in numbers are 888-203-1112 (domestic) and 719-457-0820 (international), and the access code for the replay is 3375475. Investors can also access a live web-cast of the call through a link posted on the investor page on Molecular Devices' website (http://www.moleculardevices.com/). A replay of the web-cast will be available at this location from July 20, 2006 to such time as the Company reports its financial results for the third quarter of 2006. About Molecular Devices Corporation Molecular Devices Corporation is a leading supplier of high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. The Company's systems and consumables enable pharmaceutical and biotechnology companies to leverage advances in genomics, proteomics and parallel chemistry to facilitate the high-throughput and cost-effective identification and evaluation of drug candidates. The Company's solutions are based on its advanced core technologies that integrate its expertise in engineering, molecular and cell biology and chemistry. Molecular Devices enables its customers to improve research productivity and effectiveness, which ultimately accelerates the complex process of discovering and developing new drugs. This press release contains "forward-looking" statements, including statements related to the markets for our products and future revenues and earnings. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Molecular Devices Corporation to differ materially from those indicated by these forward-looking statements, including, among others, risks related to variations in the amount of time that it takes for the Company to sell its products and collect accounts receivable, the timing of customer orders and the Company's dependence on orders that are shipped in the same quarter, which gives the Company limited visibility of future product shipments, risks related to increased competition, risks associated with the Company's need to develop new and enhanced products and other risks detailed from time to time in the Company's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2006. Molecular Devices Corporation does not undertake any obligation to update forward-looking statements. MOLECULAR DEVICES CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) Three Months Ended Six Months Ended June 30, June 30, 2006 2005 2006 2005 ----------------------------------- (unaudited) (unaudited) REVENUES $47,385 $44,537 $87,381 $83,602 COST OF REVENUES * 17,625 17,600 33,086 32,647 -------- -------- -------- -------- GROSS PROFIT 29,760 26,937 54,295 50,955 -------- -------- -------- -------- OPERATING EXPENSES: Research and development * 5,881 6,309 11,346 12,535 Write-off of acquired in-process research and development 4,272 -- 4,272 -- Selling, general and administrative * 17,593 14,593 33,839 28,907 -------- -------- -------- -------- Total operating expenses 27,746 20,902 49,457 41,442 -------- -------- -------- -------- INCOME FROM OPERATIONS 2,014 6,035 4,838 9,513 Gain on sale of equity securities -- -- 1,669 -- Interest and other income (expense), net 92 (123) 344 (602) -------- -------- -------- -------- INCOME BEFORE TAXES 2,106 5,912 6,851 8,911 Income tax provision * (2,564) (2,247) (4,463) (3,402) -------- -------- -------- -------- NET INCOME (LOSS) $(458) $3,665 $2,388 $5,509 ======== ======== ======== ======== BASIC NET INCOME (LOSS) PER SHARE $(0.03) $0.22 $0.14 $0.32 ======== ======== ======== ======== DILUTED NET INCOME (LOSS) PER SHARE $(0.03) $0.21 $0.14 $0.32 ======== ======== ======== ======== SHARES USED IN COMPUTING BASIC NET INCOME (LOSS) PER SHARE 16,806 16,872 16,815 16,989 ======== ======== ======== ======== SHARES USED IN COMPUTING DILUTED NET INCOME (LOSS) PER SHARE 16,806 17,135 17,326 17,261 ======== ======== ======== ======== * Includes the following amounts related to stock-based compensation expense recorded under FAS 123R: Cost of revenues $109 $ -- $214 $ -- Research and development 265 -- 549 -- Selling, general and administrative 920 -- 1,814 -- Income tax benefit (351) -- (742) -- ------- ------- ------- ------- Effect on net income $943 $ -- $1,835 $ -- (loss) ======= ======= ======= ======= Adjustments have been made to amounts previously reported for interest and other income (expense) net, income before taxes, income tax provision, net income (loss), basic net income (loss) per share, and diluted net income (loss) per share for 2005. We recognized $0.1 million and $0.6 million of additional pre-tax expense associated with foreign currency transaction losses on short-term intercompany receivables and payables in the second quarter and first six months of 2005, respectively. These amounts had previously been recorded as a component of stockholders' equity. In the first six months of 2005, these adjustments decreased basic net income (loss) per share by $0.03. Basic net income (loss) per share was not affected in the second quarter of 2005. In the second quarter and first six months of 2005, these adjustments decreased diluted net income (loss) per share by $0.01 and $0.02, respectively. MOLECULAR DEVICES CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) June 30, December 31, 2006 2005 ---------------------------- ASSETS (unaudited) Current assets: Cash and cash equivalents $17,656 $28,908 Accounts receivable, net 38,256 41,197 Inventories, net 26,919 23,197 Deferred tax assets 5,875 5,873 Prepaids and other current assets 2,326 2,353 ---------- ---------- Total current assets 91,032 101,528 Equipment and leasehold improvements, net 10,394 9,902 Other assets 152,232 145,986 ---------- ---------- $253,658 $257,416 ========== ========== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $8,444 $7,676 Accrued liabilities 25,007 31,188 ---------- ---------- Total current liabilities 33,451 38,864 Long-term liabilities: Other long-term liabilities 1,083 993 Deferred tax liabilities 4,486 4,486 ---------- ---------- Total long-term liabilities 5,569 5,479 Stockholders' equity 214,638 213,073 ---------- ---------- $253,658 $257,416 ========== ========== HISTORICAL NON-GAAP RECONCILIATION (unaudited) (in thousands, except per share amounts) Three Months Ended June 30, 2006 --------------------------------------- Non-GAAP Adjustments ---------------------- Write- off of acquired GAAP FAS 123R IPR&D Non-GAAP --------------------------------------- REVENUES $47,385 $ -- $ -- $47,385 COST OF REVENUES 17,625 (109) -- 17,516 --------------------------------------- GROSS PROFIT 29,760 109 -- 29,869 --------------------------------------- OPERATING EXPENSES: Research and development 5,881 (265) -- 5,616 Write-off of acquired in-process research and development 4,272 -- (4,272) -- Selling, general and administrative 17,593 (920) -- 16,673 --------------------------------------- Total operating expenses 27,746 (1,185) (4,272) 22,289 --------------------------------------- INCOME FROM OPERATIONS 2,014 1,294 4,272 7,580 Interest and other income, net 92 -- -- 92 --------------------------------------- INCOME BEFORE TAXES 2,106 1,294 4,272 7,672 Income tax provision (2,564) (351) -- (2,915) --------------------------------------- NET INCOME (LOSS) $(458) $943 $4,272 $4,757 ======================================= BASIC NET INCOME (LOSS) PER SHARE $(0.03) $0.06 $0.25 $0.28 ======================================= DILUTED NET INCOME (LOSS) PER SHARE $(0.03) $0.05 $0.25 $0.28 ======================================= SHARES USED IN COMPUTING BASIC NET INCOME (LOSS) PER SHARE 16,806 16,806 16,806 16,806 ======================================= SHARES USED IN COMPUTING DILUTED NET INCOME (LOSS) PER SHARE * 16,806 17,277 17,277 17,277 ======================================= Six Months Ended June 30, 2006 --------------------------------------- Non-GAAP Adjustments ---------------------- Other recon- ciling GAAP FAS 123R items Non-GAAP --------------------------------------- REVENUES $87,381 $ -- $ -- $87,381 COST OF REVENUES 33,086 (214) -- 32,872 --------------------------------------- GROSS PROFIT 54,295 214 -- 54,509 --------------------------------------- OPERATING EXPENSES: Research and development 11,346 (549) -- 10,797 Write-off of acquired in-process research and development 4,272 -- (4,272) -- Selling, general and administrative 33,839 (1,814) -- 32,025 --------------------------------------- Total operating expenses 49,457 (2,363) (4,272) 42,822 --------------------------------------- INCOME FROM OPERATIONS 4,838 2,577 4,272 11,687 Gain on sale of equity securities 1,669 -- (1,669) -- Interest and other income, net 344 -- -- 344 --------------------------------------- INCOME BEFORE TAXES 6,851 2,577 2,603 12,031 Income tax provision (4,463) (742) 634 (4,571) --------------------------------------- NET INCOME $2,388 $1,835 $3,237 $7,460 ======================================= BASIC NET INCOME PER SHARE $0.14 $0.11 $0.19 $0.44 ======================================= DILUTED NET INCOME PER SHARE $0.14 $0.11 $0.19 $0.43 ======================================= SHARES USED IN COMPUTING BASIC NET INCOME PER SHARE 16,815 16,815 16,815 16,815 ======================================= SHARES USED IN COMPUTING DILUTED NET INCOME PER SHARE * 17,326 17,326 17,326 17,326 ======================================= * For the three and six months ended June 30, 2006, the Company did not adjust the shares used in computing non-GAAP diluted net income per share to conform to what the diluted shares would have been had it applied prior accounting standards. The difference between the shares calculated by applying FAS 123R and calculated under prior accounting standards for the three and six months ended June 30, 2006 was approximately 0.1 million shares and is immaterial. NON-GAAP MEASURES Each non-GAAP financial measure presented in this press release is included because Molecular Devices Corporation's management uses this information for internal planning and forecasting purposes as well as to monitor and evaluate on-going operating results and trends excluding the impact of FAS 123R and the unusual items related to the gain on the sale of an equity investment and the write-off of acquired in-process research and development. Molecular Devices' management believes that such non-GAAP financial measures are also useful for investors because the gain on the sale of an equity investment and the write-off of acquired in-process research and development are the results of transactions that are unusual due to their nature, size and frequency. In addition, excluding the impact of FAS 123R permits a more direct comparison to results in 2005, at which time FAS 123R had not yet been adopted. Consequently, excluding the impact of FAS 123R, the gain on the sale of an equity investment and the write-off of acquired in-process research and development from Molecular Devices' operating results provides investors an important insight into Molecular Devices' operating results and related trends of its core business. In addition, excluding the impact of FAS 123R, the gain on the sale of an equity investment and the write-off of acquired in-process research and development from Molecular Devices' financial guidance provides meaningful supplementary information to both management and investors that is indicative of Molecular Devices' core operating results and enhances an overall understanding of Molecular Devices' prospects for the future. DATASOURCE: Molecular Devices Corporation CONTACT: Tim Harkness, Molecular Devices Corporation, +1-408-747-3533 Web site: http://www.moleculardevices.com/

Copyright